Global Urinalysis Market Size, Share, Opportunities, And Trends By Product Type (Instruments (Automated Urine Analyzer, Semi-automated Urine Analyzer, Point-of-Care Urine Analyzer), Consumables (Reagents, Kits, Dipsticks, Disposables)), By Test Type (Biochemical Urinalysis, Pregnancy & Fertility Urinalysis, Sediment Urinalysis), By Applications (Urinary Tract Infections, Diabetes, Kidney Diseases, Liver Diseases, Pregnancy And Fertility, Others), By End User (Hospitals And Clinics, Diagnostic Laboratories, Research & Academic Institutions, Home Care Settings), And By Geography - Forecasts From 2025 To 2030

The global urinalysis market is expected to grow at a compound annual growth rate of 6.44% over the forecast period to reach a market size of US$7.088 billion in 2030 from US$4.296 billion in 2025.

Urinalysis is a urine test that is used to diagnose and treat a variety of conditions, including urinary tract infections (UTI), kidney disease, and diabetes. During a urinalysis, the appearance, concentration, and content of urine are all evaluated. Abnormal urine findings may indicate a condition or illness. In September 2021, according to Eurek Aert, the Translational Genomics Research Institute (TGen), a City of Hope affiliate, discovered a method to pinpoint early-stage cancer by utilizing Urinalysis to analyze small strands of cell-free DNA in urine. Various non-invasive urine automated analyzers have been developed to provide rapid and accurate test results.

The increased prevalence of UTIs, diabetes, and kidney and liver disorders, as well as the growing geriatric population and the resulting increase in age-related diseases, are driving market expansion. In hospitals and other critical care units and medical-surgical units, the prevalence of conditions such as UTI, renal disease, and diabetes is likely to be greater. According to the National Centre of Biotechnology Information, one-third of women will have experienced a UTI by the age of 24 and half by the age of 32.

Additionally, according to the International Diabetes Federation, about 463 million individuals between the age of 20-79 years had diabetes in 2019, and this number is expected to grow to 700 million by 2045. Furthermore, according to the National Kidney Foundation, chronic kidney disease (CKD) affects 10% of the world's population, with millions dying each year.

However, the market expansion is likely to be hampered in the coming years by a strict regulatory framework and an unfavorable reimbursement condition.

Market Drivers:

• Rising geriatric population and age-related diseases are anticipated to increase the global urinalysis market.

The growing geriatric population in developed and developing countries will boost the urinalysis market growth. According to the World Health Organization, the number of adults aged 60 and more will surpass children under the age of five by 2020. The prevalence of age-related diseases such as diabetes and kidney and liver disease is projected to rise dramatically as the geriatric population grows.

According to the International Diabetes Organization, one in every five persons over the age of 65 has diabetes. Prescriptions for tests such as creatinine, albumin, glucose, ketones, and bilirubin, among others, are on the rise as a result of the increased diagnosis and treatment of such disorders, which is benefiting urinalysis, which is used to perform these tests.

Market Restraints:

• Unfavorable reimbursement conditions could hamper the global urinalysis market.

The availability of refurbished instruments, which provide the same functionality as new equipment at a cheaper cost, poses a barrier to market growth. Several end customers, primarily small and medium-sized laboratories, choose cost-effective reconditioned equipment. Particularly in developing nations, where markets are price-sensitive, inexpensive instruments with equivalent functions are preferred. This is likely to limit the revenue of companies that sell branded analyzers, thus limiting the market growth.

The North American region is projected to have a significant marketplace.

Due to an aging population and a high prevalence of CKD, the North American market is projected to have a significant market position. Kidney failure, high blood pressure, and diabetes are all linked to CKD. According to the National Kidney Foundation, more people die due to CKD than breast cancer and prostate cancer each year. In the United States, kidney disease is a major cause of death. It now affects around 37 million individuals in the US. It is more common in the aging population, affecting around 15% of the adult population.

Kidney disease affects around one in every three individuals with diabetes and one in every five adults with high blood pressure. Hence, there is a growing demand for accurate detection and treatment of CKD, and these factors are likely to drive up demand for urinalysis.

Key Developments:

• December 2023- Siemens Healthineers introduced the Atellica UAS 60 Analyzer, a digital solution for urine sediment analysis. This automated tool replaces manual microscopy, enabling quicker and more accurate results review and reporting. It generates 15 high-resolution digital images per sample, features auto Image Evaluation Module technology for automatic identification of particles, live-view mode for movement visualization, and automatic bacterial subcategorization for easier identification of CKD and UTI.
• November 2022- EmeritusDX and KDx Diagnostics Inc. partnered to offer the URO17 non-invasive urine test for bladder cancer detection. URO17 is a highly sensitive and negative predicted value (NPV) test that can determine the status of active bladder cancer and improve patient diagnosis. It is available as a Laboratory Developed Test in the US, allowing EmeritusDX to offer URO17 testing to Urology practices nationwide. The test can rule out patients with micro-hematuria for unnecessary cystoscopy and reduce the work-up.
• October 2022- Olive Diagnostics, an IoMT MedTech startup, received the European CE Mark for its innovative AI-based urine analysis device, the Olive KG. The device is the world's first hands-free, non-invasive, AI-based optical device for passive and seamless urinalysis mounted on any toilet. It performs high-quality analysis of important parameters in patients' urine without user intervention, measuring red blood cells, proteins, Nitrites, pH levels, volume, pressure, color, and frequency of urination. The device generates real-time personal data, secured according to GDPR and HIPPA requirements, which is sent to the cloud and treated by the treating physician.
• September 2022- Sysmex Corporation introduced the UF-1500 Fully Automated Urine Particle Analyzer (UF-1500), a new product for urine sediment testing. The UF-1500 inherits the functionality and usability of the UF-5000 model but is downsized. It offers a wider range of solutions tailored to customers' environments and contributes to streamlining and standardization of urine testing at small and medium-sized facilities. The UF-1500 supports connectivity with transportation systems for urine chemistry analyzers, meeting various customer needs, including demand from small and medium-sized facilities and backup systems from large facilities.

Global Urinalysis Market Scope:

Report Metric	Details
Market Size Value in 2025	US$4.296 billion
Market Size Value in 2030	US$7.088 billion
Growth Rate	CAGR of 6.44%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segments Covered	Product Type Test Type Application End-User Geography
Companies Covered	ARKRAY, Inc. 77 Elektronika Kft. Siemens Healthineers AG F. Hoffmann-La Roche Ltd. Beckman Coulter, Inc.
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Customization Scope	Free report customization with purchase

 

Market Segmentation:

• By Product Type
  • Instruments
    • Automated Urine Analyzer
    • Semi-automated Urine Analyzer
    • Point-of-Care Urine Analyzer
  • Consumables
    • Reagents
    • Kits
    • Dipsticks
    • Disposables
• By Test Type
  • Biochemical Urinalysis
  • Pregnancy & Fertility Urinalysis
  • Sediment Urinalysis
• By Application
  • Urinary Tract Infections
  • Diabetes
  • Kidney Diseases
  • Liver Diseases
  • Pregnancy and Fertility
  • Others
• By End-User
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutions
  • Home Care Settings
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Others
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. GLOBAL URINALYSIS MARKET BY PRODUCT TYPE

5.1. Introduction

5.2. Instruments

5.2.1. Market Opportunities and Trends

5.2.2. Growth Prospects

5.2.3. Geographic Lucrativeness

5.2.4. Automated Urine Analyzer

5.2.5. Semi-automated Urine Analyzer

5.2.6. Point-of-Care Urine Analyzer

5.3. Consumables

5.3.1. Market Opportunities and Trends

5.3.2. Growth Prospects

5.3.3. Geographic Lucrativeness

5.3.4. Reagents

5.3.5. Kits

5.3.6. Dipsticks

5.3.7. Disposables

6. GLOBAL URINALYSIS MARKET BY TEST TYPE

6.1. Introduction

6.2. Biochemical Urinalysis

6.2.1. Market Opportunities and Trends

6.2.2. Growth Prospects

6.2.3. Geographic Lucrativeness

6.3. Pregnancy & Fertility Urinalysis

6.3.1. Market Opportunities and Trends

6.3.2. Growth Prospects

6.3.3. Geographic Lucrativeness

6.4. Sediment Urinalysis

6.4.1. Market Opportunities and Trends

6.4.2. Growth Prospects

6.4.3. Geographic Lucrativeness

7. GLOBAL URINALYSIS MARKET BY APPLICATION

7.1. Introduction

7.2. Urinary Tract Infections

7.2.1. Market Opportunities and Trends

7.2.2. Growth Prospects

7.2.3. Geographic Lucrativeness

7.3. Diabetes

7.3.1. Market Opportunities and Trends

7.3.2. Growth Prospects

7.3.3. Geographic Lucrativeness

7.4. Kidney Diseases

7.4.1. Market Opportunities and Trends

7.4.2. Growth Prospects

7.4.3. Geographic Lucrativeness

7.5. Liver Diseases

7.5.1. Market Opportunities and Trends

7.5.2. Growth Prospects

7.5.3. Geographic Lucrativeness

7.6. Pregnancy and Fertility

7.6.1. Market Opportunities and Trends

7.6.2. Growth Prospects

7.6.3. Geographic Lucrativeness

7.7. Others

7.7.1. Market Opportunities and Trends

7.7.2. Growth Prospects

7.7.3. Geographic Lucrativeness

8. GLOBAL URINALYSIS MARKET BY END-USER

8.1. Introduction

8.2. Hospitals & Clinics

8.2.1. Market Opportunities and Trends

8.2.2. Growth Prospects

8.2.3. Geographic Lucrativeness

8.3. Diagnostic Laboratories

8.3.1. Market Opportunities and Trends

8.3.2. Growth Prospects

8.3.3. Geographic Lucrativeness

8.4. Research & Academic Institutions

8.4.1. Market Opportunities and Trends

8.4.2. Growth Prospects

8.4.3. Geographic Lucrativeness

8.5. Home Care Settings

8.5.1. Market Opportunities and Trends

8.5.2. Growth Prospects

8.5.3. Geographic Lucrativeness

9. GLOBAL URINALYSIS MARKET BY GEOGRAPHY

9.1. Introduction

9.2. North America

9.2.1. By Product Type

9.2.2. By Test Type

9.2.3. By Application

9.2.4. By End-User

9.2.5. By Country

9.2.5.1. USA

9.2.5.1.1. Market Opportunities and Trends

9.2.5.1.2. Growth Prospects

9.2.5.2. Canada

9.2.5.2.1. Market Opportunities and Trends

9.2.5.2.2. Growth Prospects

9.2.5.3. Mexico

9.2.5.3.1. Market Opportunities and Trends

9.2.5.3.2. Growth Prospects

9.3. South America

9.3.1. By Product Type

9.3.2. By Test Type

9.3.3. By Application

9.3.4. By End-User

9.3.5. By Country 

9.3.5.1. Brazil

9.3.5.1.1. Market Opportunities and Trends

9.3.5.1.2. Growth Prospects

9.3.5.2. Argentina

9.3.5.2.1. Market Opportunities and Trends

9.3.5.2.2. Growth Prospects

9.3.5.3. Others

9.3.5.3.1. Market Opportunities and Trends

9.3.5.3.2. Growth Prospects

9.4. Europe

9.4.1. By Product Type

9.4.2. By Test Type

9.4.3. By Application

9.4.4. By End-User

9.4.5. By Country

9.4.5.1. Germany

9.4.5.1.1. Market Opportunities and Trends

9.4.5.1.2. Growth Prospects

9.4.5.2. France

9.4.5.2.1. Market Opportunities and Trends

9.4.5.2.2. Growth Prospects

9.4.5.3. UK

9.4.5.3.1. Market Opportunities and Trends

9.4.5.3.2. Growth Prospects

9.4.5.4. Italy

9.4.5.4.1. Market Opportunities and Trends

9.4.5.4.2. Growth Prospects

9.4.5.5. Spain

9.4.5.5.1. Market Opportunities and Trends

9.4.5.5.2. Growth Prospects

9.4.5.6. Others

9.4.5.6.1. Market Opportunities and Trends

9.4.5.6.2. Growth Prospects

9.5. Middle East and Africa

9.5.1. By Product Type

9.5.2. By Test Type

9.5.3. By Application

9.5.4. By End-User

9.5.5. By Country

9.5.5.1. Saudi Arabia

9.5.5.1.1. Market Opportunities and Trends

9.5.5.1.2. Growth Prospects

9.5.5.2. UAE

9.5.5.2.1. Market Opportunities and Trends

9.5.5.2.2. Growth Prospects

9.5.5.3. South Africa

9.5.5.3.1. Market Opportunities and Trends

9.5.5.3.2. Growth Prospects

9.5.5.4. Others

9.5.5.4.1. Market Opportunities and Trends

9.5.5.4.2. Growth Prospects

9.6. Asia Pacific

9.6.1. By Product Type

9.6.2. By Test Type

9.6.3. By Application

9.6.4. By End-User

9.6.5. By Country

9.6.5.1. China

9.6.5.1.1. Market Opportunities and Trends

9.6.5.1.2. Growth Prospects

9.6.5.2. India

9.6.5.2.1. Market Opportunities and Trends

9.6.5.2.2. Growth Prospects

9.6.5.3. Japan

9.6.5.3.1. Market Opportunities and Trends

9.6.5.3.2. Growth Prospects

9.6.5.4. South Korea

9.6.5.4.1. Market Opportunities and Trends

9.6.5.4.2. Growth Prospects

9.6.5.5. Taiwan

9.6.5.5.1. Market Opportunities and Trends

9.6.5.5.2. Growth Prospects

9.6.5.6. Thailand

9.6.5.6.1. Market Opportunities and Trends

9.6.5.6.2. Growth Prospects

9.6.5.7. Indonesia

9.6.5.7.1. Market Opportunities and Trends

9.6.5.7.2. Growth Prospects

9.6.5.8. Others

9.6.5.8.1. Market Opportunities and Trends

9.6.5.8.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. ARKRAY, Inc.

11.2. 77 Elektronika Kft.

11.3. Siemens Healthineers AG

11.4. F. Hoffmann-La Roche Ltd.

11.5. Beckman Coulter, Inc.

11.6. Abbott Laboratories

11.7. Sysmex Corporation

11.8. Neomedica d.o.o.

11.9. Mindray Medical International Limited

11.10. Analis sa/nv

ARKRAY, Inc.

77 Elektronika Kft.

Siemens Healthineers AG

F. Hoffmann-La Roche Ltd.

Beckman Coulter, Inc.

Abbott Laboratories

Sysmex Corporation

Neomedica d.o.o.

Mindray Medical International Limited

Analis sa/nv